These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 26021991)

  • 1. Ceftolozane/Tazobactam Therapy of Respiratory Infections due to Multidrug-Resistant Pseudomonas aeruginosa.
    Gelfand MS; Cleveland KO
    Clin Infect Dis; 2015 Sep; 61(5):853-5. PubMed ID: 26021991
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful treatment of multidrug-resistant Pseudomonas aeruginosa breakthrough bacteremia with ceftolozane/tazobactam.
    Hernández-Tejedor A; Merino-Vega CD; Martín-Vivas A; Ruiz de Luna-González R; Delgado-Iribarren A; Gabán-Díez Á; Temprano-Gómez I; de la Calle-Pedrosa N; González-Jiménez AI; Algora-Weber A
    Infection; 2017 Feb; 45(1):115-117. PubMed ID: 27670678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceftolozane-tazobactam for the treatment of ventilator-associated infections by colistin-resistant Pseudomonas aeruginosa.
    Álvarez Lerma F; Muñoz Bermudez R; Grau S; Gracia Arnillas MP; Sorli L; Recasens L; Mico García M
    Rev Esp Quimioter; 2017 Jun; 30(3):224-228. PubMed ID: 28361526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful Use of Ceftolozane-Tazobactam to Treat a Pulmonary Exacerbation of Cystic Fibrosis Caused by Multidrug-Resistant Pseudomonas aeruginosa.
    Vickery SB; McClain D; Wargo KA
    Pharmacotherapy; 2016 Oct; 36(10):e154-e159. PubMed ID: 27522066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salvage Therapy with Ceftolozane-Tazobactam for Multidrug-Resistant Pseudomonas aeruginosa Infections.
    Castón JJ; De la Torre Á; Ruiz-Camps I; Sorlí ML; Torres V; Torre-Cisneros J
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27956431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful treatment of post-surgical osteomyelitis caused by XDR Pseudomonas aeruginosa with ceftolozane/tazobactam monotherapy.
    Gentile I; Buonomo AR; Maraolo AE; Scotto R; De Zottis F; Di Renzo G; Borgia G
    J Antimicrob Chemother; 2017 Sep; 72(9):2678-2679. PubMed ID: 28575437
    [No Abstract]   [Full Text] [Related]  

  • 7. Ceftolozane-tazobactam therapy for multidrug-resistant Pseudomonas aeruginosa infections in patients with hematologic malignancies and hematopoietic-cell transplant recipients.
    Hakki M; Lewis JS
    Infection; 2018 Jun; 46(3):431-434. PubMed ID: 29460229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance.
    Haidar G; Philips NJ; Shields RK; Snyder D; Cheng S; Potoski BA; Doi Y; Hao B; Press EG; Cooper VS; Clancy CJ; Nguyen MH
    Clin Infect Dis; 2017 Jul; 65(1):110-120. PubMed ID: 29017262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment of three severe MDR or XDR Pseudomonas aeruginosa infections with ceftolozane/tazobactam.
    Xipell M; Bodro M; Marco F; Martínez JA; Soriano A
    Future Microbiol; 2017 Nov; 12():1323-1326. PubMed ID: 28980834
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Goodlet KJ; Nicolau DP; Nailor MD
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ceftolozane/tazobactam for the treatment of XDR Pseudomonas aeruginosa infections.
    Escolà-Vergé L; Pigrau C; Los-Arcos I; Arévalo Á; Viñado B; Campany D; Larrosa N; Nuvials X; Ferrer R; Len O; Almirante B
    Infection; 2018 Aug; 46(4):461-468. PubMed ID: 29594953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2013-2016) as Part of the Surveillance Program: Program to Assess Ceftolozane-Tazobactam Susceptibility.
    Shortridge D; Pfaller MA; Castanheira M; Flamm RK
    Microb Drug Resist; 2018 Jun; 24(5):563-577. PubMed ID: 29039729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa.
    Munita JM; Aitken SL; Miller WR; Perez F; Rosa R; Shimose LA; Lichtenberger PN; Abbo LM; Jain R; Nigo M; Wanger A; Araos R; Tran TT; Adachi J; Rakita R; Shelburne S; Bonomo RA; Arias CA
    Clin Infect Dis; 2017 Jul; 65(1):158-161. PubMed ID: 28329350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ceftolozane/tazobactam sensitivity patterns in Pseudomonas aeruginosa isolates recovered from sputum of cystic fibrosis patients.
    Finklea JD; Hollaway R; Lowe K; Lee F; Le J; Jain R
    Diagn Microbiol Infect Dis; 2018 Sep; 92(1):75-77. PubMed ID: 29884565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of multidrug-resistant Pseudomonas aeruginosa with ceftolozane/tazobactam in a critically ill patient receiving continuous venovenous haemodiafiltration.
    Kuti JL; Ghazi IM; Quintiliani R; Shore E; Nicolau DP
    Int J Antimicrob Agents; 2016 Sep; 48(3):342-3. PubMed ID: 27451086
    [No Abstract]   [Full Text] [Related]  

  • 16. Ceftolozane-tazobactam resistance induced in vivo during the treatment of MDR Pseudomonas aeruginosa pneumonia.
    Plant AJ; Dunn A; Porter RJ
    Expert Rev Anti Infect Ther; 2018 May; 16(5):367-368. PubMed ID: 29727213
    [No Abstract]   [Full Text] [Related]  

  • 17. Determination of alternative ceftolozane/tazobactam dosing regimens for patients with infections due to Pseudomonas aeruginosa with MIC values between 4 and 32 mg/L.
    Natesan S; Pai MP; Lodise TP
    J Antimicrob Chemother; 2017 Oct; 72(10):2813-2816. PubMed ID: 29091209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and Wounds.
    Grupper M; Sutherland C; Nicolau DP
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emergence of Ceftolozane-Tazobactam-Resistant Pseudomonas aeruginosa during Treatment Is Mediated by a Single AmpC Structural Mutation.
    MacVane SH; Pandey R; Steed LL; Kreiswirth BN; Chen L
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28947473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).
    Sader HS; Farrell DJ; Castanheira M; Flamm RK; Jones RN
    J Antimicrob Chemother; 2014 Oct; 69(10):2713-22. PubMed ID: 24917579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.